GSK Faces Challenges Ahead with Patent Expirations Looming

GSK's CEO Luke Miels outlines a forecast showing slower sales growth by 2026 due to looming patent expirations on top-selling HIV drugs. With the need for new product launches, GSK aims to achieve £40 billion in sales by 2031. The focus remains on operational delivery amidst U.S. policy challenges.

In his first strategic forecast, GSK's new CEO Luke Miels revealed an anticipated slowdown in sales growth by 2026, driven by upcoming patent expirations impacting their leading HIV treatments.

Despite these challenges, Miels remains confident in reaching £40 billion in sales by 2031, stressing the importance of new product launches to offset the expected declines.

As GSK navigates U.S. regulatory and policy landscapes, operational execution remains vital, with this year being pivotal for the firm's long-term growth prospects.

(With inputs from agencies.)